Longevity.Technology UNLOCKED

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping longevity and proactive healthcare. From government-backed healthspan trials to next-generation brain wearables, smartphone-based health screening, ovarian longevity research, and nanotech biosensing, this episode connects science, innovation, and real-world impact.

• The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.
• Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.
• Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.
• Mainstream pharma is also advancing longevity research. Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.
• Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.
• Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity.

_____________________

News & References:

• ARPA-H pours millions into healthspan-focused human trials → https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trials
• Wearable startup Temple secures $54m for brain monitoring → https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/
• YOU(th) lands funding for smartphone-based preventive health screening → https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/
• Richter sharpens ovarian aging focus following Celmatix asset deal → https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/
• How billionaires die → https://longevity.technology/news/how-billionaires-die/
• Nanotech startup lands funding for continuous biosensing platform → https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/

_____________________

Hosts:

Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠

Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn

Guests:

Allen Law

Founder and CEO of MORROW

Linkedin:https://www.linkedin.com/in/allenlawphg/

Website:https://morrow.health/

Dr William Tan

Clinical Governance Officer of MORROW

Linkedin: https://www.linkedin.com/in/dr-william-tan-05438649/

Website: https://morrow.health/

______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link:https://www.getstride.com/unlocked/

______________________

What if longevity wasn’t a treatment… but a system you live inside every day?

In this episode, Phil Newman sits down with Allen Law, founder and CEO of Morrow, and Dr William Tan, physician-neuroscientist and Chief Governance Officer of Morrow, to explore a new model of preventive healthcare designed around daily behavior, measurable biology, and community support.

They discuss why modern medicine often reacts to disease rather than preventing it, how lifestyle medicine can be structured into actionable programs, and why most people fail to act on their health data even after testing. Allen explains how Morrow combines diagnostics, coaching, and artificial intelligence to translate biomarkers into habits, while William shares how his personal journey through disability and elite sport shaped his philosophy of proactive health.

Together, they examine accessibility in longevity care, the economics of preventive medicine, and why community engagement may be as important as any clinical intervention. The conversation also looks at Singapore’s evolving health ecosystem and how technology could scale personalized care beyond elite clinics.

In this episode, you’ll learn:

• Why preventive healthcare often fails despite widespread testing
• How Morrow connects diagnostics directly to daily lifestyle interventions
• The role of AI in turning health data into consistent habit change
• Why community and purpose influence long term health outcomes
• How accessibility could reshape the longevity clinic industry
• What Singapore’s healthcare model reveals about future global systems
• Why small consistent habits outperform short term health resolutions

If you want to understand how healthcare may shift from treating illness to designing wellbeing, and what real world longevity infrastructure could look like, this conversation offers a practical view of the future of healthspan.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest discoveries transforming longevity science. From invisible nanoplastics crossing the blood-brain barrier to first-of-its-kind Klothea mRNA human trials, wearable lactate sensors, and AI models targeting aging-linked inflammation, this episode connects science, innovation, and real-world impact.

• Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia.
• Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease.
• In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.
• Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.
• Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.
• The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.

______________________

News & References:

• Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/
• Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/
• Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/
• FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/
• Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/
• Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Alexander Zhavoronkov

Founder, CEO and CBO at Insilico Medicine

Linkedin: www.linkedin.com/in/zhavoronkov/

Website: https://insilico.com/

______________________

What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?

In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.

They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.

Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.

In this episode, you’ll learn:

• Why early diagnostics may currently be the most reliable longevity strategy.
• How AI can design drug candidates in months instead of years.- Why most longevity drugs succeed in animals but fail to prove benefits in humans.
• How disease focused therapeutics could become future aging interventions.
• What GLP-1 drugs reveal about the future of longevity medicine.
• The real role of clinical trials in validating AI generated therapies.
• How next generation technologies like brain computer interfaces could extend healthy lifespan.

If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity.

• Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.
• London-based GenFlow Biosciences released preliminary data from its SIRT6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.
• In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.
• In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.
• Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.
• Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable.

______________________

News & References:

• What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/
• Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/
• New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/
• As obesity drugs go oral and access grows, so do fakes → https://longevity.technology/news/as-obesity-drugs-go-oral-and-access-grows-so-do-fakes/
• Genflow reveals early data from SIRT6 gene therapy trial in dogs → https://longevity.technology/news/genflow-reveals-early-data-from-sirt6-gene-therapy-trial-in-dogs/
• Amazon makes longevity move with Lifeforce collab → https://longevity.technology/news/amazon-makes-longevity-move-with-lifeforce-collab/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Christian Drapeau

Founder + Chief Science Officer of STEMREGEN

Instagram: https://www.instagram.com/stemcellchristian/

Website: https://www.stemregen.co/

______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

______________________

What if your body had a repair system that could predict and prevent age-related disease?

Phil Newman and Dr. Nina Patrick sit down with Christian Drapeau, a researcher and expert in stem cells and regenerative biology. Christian explains how stem cells act as the body’s natural repair system, why measuring them could become a key biomarker for health, and how lifestyle factors, diet, and specific plant compounds can optimize their activity.

They explore the science behind stem cell release, how exercise, fasting, meditation, sauna, and cold exposure support regeneration, and the emerging technologies helping stem cells reach their full potential. Christian also discusses targeted applications for heart repair, joint health, and other tissues, as well as the future of accessible stem cell measurement.

This conversation highlights that supporting longevity goes beyond lifestyle hacks or clinical treatments. Christian’s research shows that understanding stem cell biology, preparing the body’s “terrain” for repair, and aligning interventions with evidence-based science are all critical for extending healthspan and improving long-term quality of life.

In this episode, you’ll learn:

• Why stem cells are the cornerstone of the body’s repair system
• How measuring stem cells could predict age-related disease and track health
• Lifestyle and diet strategies to naturally boost stem cell release
• How technology like PMF, sauna, and cold exposure works with stem cells
• Targeted stem cell applications for heart, joints, and tissue repair care

If you care about protecting your long-term health and want to understand how science, technology, and clinical strategies intersect to shape the future of healthspan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies, interventions, and technologies helping us understand and harness the body’s natural repair systems.

______________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: https://qrco.de/bgXpKn

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox.

• Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a regulatory precedent for aging as an approvable indication.
• Decoding Longevity Trends, a new AI-native platform tracking over 600 longevity-focused companies, including pipelines, mechanisms of action, and clinical stages. The system features a chatbot for complex queries and aims to accelerate insights for investors, pharma, and operators in the longevity ecosystem.
• Cambiotics, a Copenhagen-based startup, raised $4 million to develop 46and, a probiotic supplement designed to help the body eliminate PFAS (“forever chemicals”). Early research shows specific gut bacteria can bind PFAS, with human trials expected in the US this year, marking a step forward in exposome-based longevity interventions.
• In neurodegeneration news, Vector Y dosed its first patient in a Phase 1 trial for VTX002, a one-time gene therapy targeting TDP43 pathology in ALS. This vectorized antibody approach installs a long-term antibody factory in the CNS, potentially transforming treatment from repeated dosing to durable, one-shot interventions and extending to other neurodegenerative conditions.
• The biohacking and self-managed health sector is projected to hit $216 billion by 2035, led by North America. Wearables, diagnostics, genetics, and personalized health platforms are driving adoption, while longevity and neuroscience increasingly intersect with consumer-driven biohacking practices.
• Backed by a five-year, $3.3 million federal award, a new research initiative at Oregon Health & Science University (OHSU) aims to develop a retinal screening tool that could flag the earliest biological signals of Alzheimer’s using nothing more than an eye drop and a quick scan.

______________________

News & References:

• Loyal raises $100m as canine longevity drug nears approval → https://longevity.technology/news/loyal-raises-100m-as-canine-longevity-drug-nears-approval/
• VectorY doses first patient in ALS gene therapy trial → https://longevity.technology/news/vectory-doses-first-patient-in-als-gene-therapy-trial/
• Longevity.Technology unveils DLT – the intelligence platform for longevity → https://longevity.technology/news/longevity-technology-unveils-dlt-the-intelligence-platform-for-longevity
• Danish startup aims to remove ‘forever chemicals’ from the body → https://longevity.technology/news/danish-startup-aims-to-remove-forever-chemicals-from-the-body/
• Biohacking market projected to top US$216 billion by 2035 → https://longevity.technology/news/biohacking-market-projected-to-top-us216-billion-by-2035/
• New retinal screening targets Alzheimer’s before memory loss → https://longevity.technology/news/new-retinal-screening-targets-alzheimers-before-memory-loss/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:

Carolyn Ringel, JD, MBE
Consultant and Instructor for Harvard Medical School Center for Bioethics
LinkedIn: https://www.linkedin.com/in/carolyn-baker-ringel-35378431/

David Barzilai, MD, PhD, MBA, MS, DipABLM
Founder and CEO of Barzilai Longevity Consulting
LinkedIn: https://www.linkedin.com/in/agingdoc/
Website: https://www.barzilaiconsulting.com/david

________________

Longevity ethics? What if extending healthspan required rethinking not just medicine, but society itself?

Phil Newman and Dr. Nina Patrick sit down with Carolyn Ringel, a bioethicist at Harvard Medical School, and Dr. David Barzilai, a longevity medicine physician. They explore how aging research and geroscience can address urgent health issues like heart disease, diabetes, cancer, and dementia, while highlighting the ethical responsibilities of science and medicine.

Carolyn emphasizes that studying aging is not an either-or with addressing current health crises; by understanding aging, we can better prevent and treat age-related diseases. She also explores how healthcare funding, housing, and social infrastructure can be designed to support longer, healthier lives, creating a society where longevity benefits everyone.

David explains the importance of trusted patient-doctor relationships, scientific literacy, and emerging interventions like aging biomarkers, cellular reprogramming, and regenerative medicine. He highlights the potential of integrated, systems-based approaches and AI-driven research to accelerate the development of safe, effective longevity strategies.

This conversation highlights that longevity is not just about supplements, exercise, or clinical interventions. Ethical frameworks, societal design, and evidence-based medicine all play a crucial role in extending healthspan and improving quality of life.

In this episode, you’ll learn:

• How geroscience can prevent multiple age-related diseases simultaneously
• The ethical considerations of patient empowerment and longevity interventions
• How societal infrastructure and healthcare funding can support longer, healthier lives
• The role of biomarkers and AI in safe, effective longevity strategies
• The future of integrated, evidence-based, and ethical longevity care

If you care about protecting your long-term health and want to understand how ethics, policy, and science intersect to shape the future of healthspan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies, policies, and strategies

________________

Connect with our hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠

Dr. Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity, from new insights into genetic influence on lifespan to reproductive longevity, exosome therapeutics, AI health platforms, epigenetic reprogramming, and psychedelics for cognitive resilience.

• New research challenges long-standing estimates of genetic contribution to lifespan. When deaths caused by environmental factors are separated from intrinsic aging, heritability for intrinsic lifespan rises to around 50–55%, doubling previous assumptions and reshaping how we think about early interventions.
• Gameto licenses meiosis induction technology from Harvard to create ovarian organoids in a dish, opening a platform for women’s reproductive longevity, drug testing during pregnancy, and potentially improved menopause therapeutics.
• Houston-based Prana X Corp raises $17 million to develop exosome-based regenerative biologics, applying techniques initially developed for oncology toward healthy aging, inflammation reduction, and tissue repair.
• Digital health is evolving with AI concierge platforms like Death Clock and family-focused monitoring systems like Lufu, which track health data across households to drive actionable behavior change and support intergenerational wellbeing.
• Life Biosciences receives FDA approval for the first human trial of partial epigenetic reprogramming therapy ER100, targeting retinal cells in serious age-related eye disease. This milestone moves longevity science from theory to first-in-human application with the potential to expand to other organs and systemic age reversal.
• Psychedelics are re-emerging as potential tools for cognitive resilience and emotional health in older adults, with early studies showing unexpected benefits in Parkinson’s patients and implications for preventative approaches to mental health and neuroplasticity.

______________________

News & References:

• Genes reclaim center stage in longevity debate → https://longevity.technology/news/genes-reclaim-center-stage-in-longevity-debate/
• The regulatory path for rescheduling psychedelics for healthspan → https://longevity.technology/news/the-regulatory-path-for-rescheduling-psychedelics-for-healthspan/
• FDA clears first human trial of epigenetic reprogramming therapy → https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/
• Death prediction app launches ‘AI health concierge’ → https://longevity.technology/news/death-prediction-app-launches-ai-health-concierge/
• Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform → https://longevity.technology/news/gameto-licenses-harvard-meiosis-ip-to-advance-human-ovary-in-a-dish-platform/
• PranaX lands $17m to harness exosomes in regenerative biologics → https://longevity.technology/news/pranax-lands-17m-to-harness-exosomes-in-regenerative-biologics/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest:

Dr Hany Demian
CEO, Praesentia Healthcare
Website: https://drdemian.com/
LinkedIn: https://www.linkedin.com/in/hany-demian-md-5b79b659/

_________________

What if chronic pain wasn’t just something to manage, but a key signal of deeper biological stress? And what if regenerative medicine could play a role in protecting long-term health and function?

In conversation with Phil Newman and Dr. Nina Patrick, Dr. Hany Demian explores how regenerative medicine and peptide-based therapies are being used to support recovery, mobility, and healthy aging. He explains how chronic pain is often linked to inflammation, metabolic dysfunction, and impaired tissue repair rather than isolated injury.

Dr. Demian highlights how tools such as PRP, peptides, cell-based therapies, and AI-assisted diagnostics can optimize repair, monitor progress, and guide personalized treatment plans, all while maintaining ethical, patient-centered care. The conversation shows how individualized protocols, informed by AI and clinical oversight, can improve outcomes without relying on one-size-fits-all solutions.

This discussion reinforces that longevity is not only about supplements or exercise. Addressing pain, inflammation, and tissue health with precision medicine is a critical but often overlooked component of healthspan.

In this episode, you’ll learn:

• How chronic pain affects long-term health
• Why regenerative approaches focus on repair, not symptom masking
• The role of AI and personalized treatment planning
• How ethical oversight matters in regenerative care
• What the future of regenerative medicine may hold

If you care about protecting mobility, reducing chronic pain, and supporting long-term healthspan, this is a conversation you won’t want to miss.

Subscribe for weekly episodes exploring longevity science, healthspan optimization, and emerging regenerative therapies.

________________

Connect with our hosts:

Phil Newman: ⁠https://qrco.de/bgXpNY

Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn